RAD011 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 3 |
193. プラダー・ウィリ症候群
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05387798 (ClinicalTrials.gov) | January 2023 | 17/5/2022 | A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: RAD011 | Radius Pharmaceuticals, Inc. | NULL | Withdrawn | 8 Years | 65 Years | All | 0 | Phase 3 | NULL |
| 2 | NCT05098509 (ClinicalTrials.gov) | April 13, 2022 | 22/9/2021 | A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome | Prader-Willi Syndrome | Drug: RAD011;Drug: Placebo | Radius Pharmaceuticals, Inc. | NULL | Terminated | 8 Years | 65 Years | All | 7 | Phase 2/Phase 3 | United States |
| 3 | EUCTR2021-005331-23-SE (EUCTR) | 18/05/2022 | A Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome | Hyperphagia related behavior associated with Prader-Willi Syndrome MedDRA version: 20.0;Level: PT;Classification code 10020710;Term: Hyperphagia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: RAD011 Product Code: RAD011 INN or Proposed INN: Cannabidiol | Radius Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 220 | Phase 2;Phase 3 | France;United States;Canada;Belgium;Spain;Australia;United Kingdom;Italy;Sweden |